Technical Analysis for IMVT - Immunovant, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Doji - Bullish? | Reversal | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Doji - Bullish? | Reversal | -0.35% | |
| Stochastic Reached Oversold | Weakness | -0.35% | |
| Below Lower BB | Weakness | -0.35% |
| Alert | Time |
|---|---|
| Down 3% | about 15 hours ago |
| Possible NR7 | about 16 hours ago |
| 60 Minute Opening Range Breakdown | about 19 hours ago |
| Down 2 % | about 20 hours ago |
| Fell Below Previous Day's Low | about 20 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immune System Eye Antibodies Autoimmune Disease Monoclonal Antibodies Monoclonal Antibody Anemia Thyroid Eye Diseases Treatment Of Autoimmune Disease Myasthenia Gravis Transfusion Medicine Myasthenia Thyroid Eye Disease Acquired Hemolytic Anemia Treatment Of Myasthenia Gravis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immune System Eye Antibodies Autoimmune Disease Monoclonal Antibodies Monoclonal Antibody Anemia Thyroid Eye Diseases Treatment Of Autoimmune Disease Myasthenia Gravis Transfusion Medicine Myasthenia Thyroid Eye Disease Acquired Hemolytic Anemia Treatment Of Myasthenia Gravis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 45.58 |
| 52 Week Low | 15.39 |
| Average Volume | 1,169,457 |
| 200-Day Moving Average | 31.92 |
| 50-Day Moving Average | 33.03 |
| 20-Day Moving Average | 30.70 |
| 10-Day Moving Average | 29.85 |
| Average True Range | 1.52 |
| RSI (14) | 33.33 |
| ADX | 17.1 |
| +DI | 12.05 |
| -DI | 25.81 |
| Chandelier Exit (Long, 3 ATRs) | 31.41 |
| Chandelier Exit (Short, 3 ATRs) | 31.89 |
| Upper Bollinger Bands | 33.15 |
| Lower Bollinger Band | 28.26 |
| Percent B (%b) | -0.01 |
| BandWidth | 15.92 |
| MACD Line | -1.16 |
| MACD Signal Line | -1.02 |
| MACD Histogram | -0.1438 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 30.19 | ||||
| Resistance 3 (R3) | 30.11 | 29.37 | 29.86 | ||
| Resistance 2 (R2) | 29.37 | 28.87 | 29.41 | 29.75 | |
| Resistance 1 (R1) | 28.80 | 28.56 | 28.43 | 28.88 | 29.64 |
| Pivot Point | 28.06 | 28.06 | 27.88 | 28.10 | 28.06 |
| Support 1 (S1) | 27.49 | 27.56 | 27.12 | 27.56 | 26.80 |
| Support 2 (S2) | 26.75 | 27.25 | 26.79 | 26.69 | |
| Support 3 (S3) | 26.18 | 26.75 | 26.58 | ||
| Support 4 (S4) | 26.25 |
